Results 21 to 30 of about 3,923 (195)

ARC in Critical Ill OLT Recipients: True Prevalence, Risk Factors, and Impact on Early Aggressive PK/PD Target Non‐Attainment of CI Beta‐Lactam Therapy for Posttransplant Gram‐Negative Infections [PDF]

open access: yesTransplant Infectious Disease, Volume 28, Issue 5, September/October 2026.
Augmented renal clearance (ARC) represents a quite prevalent condition among critical orthotopic liver transplant recipients (23.2%). ARC is associated with different demographics and clinical features and significantly affects the attainment of aggressive beta‐lactams pharmacokinetic/pharmacodynamic targets despite the administration of standard ...
Milo Gatti   +6 more
wiley   +2 more sources

Rapid meropenem/vaborbactam NP test for detecting susceptibility/resistance in Enterobacterales [PDF]

open access: yesJournal of Antimicrobial Chemotherapy, 2023
Abstract Background The treatment options for infections caused by carbapenem-resistant Enterobacterales (CRE) are extremely scarce nowadays and the development of new antibiotics does not follow the exponential increase in the dissemination of carbapenem resistance determinants worldwide.
Patrice Nordmann   +5 more
openaire   +5 more sources

NCY‐1 β‐Lactamase Activity Correlates With Antimicrobial Susceptibility of a Clinical Strain of Nocardia cyriacigeorgica [PDF]

open access: yesMicrobiologyOpen, Volume 15, Issue 2, April 2026.
This study shows a strong correlation between the β‐lactam susceptibility profile of a clinical isolate of Nocardia cyriacigeorgica and the activity of its β‐lactamase, NCY‐1. Inhibitors of NCY‐1 reduce the minimum inhibitory concentration of amoxicillin.
Julie Couston   +8 more
wiley   +2 more sources

Flow cytometry enables rapid evaluation of novel, new and niche antimicrobial agents [PDF]

open access: yesFrontiers in Microbiology
The global rise of multidrug-resistant bacteria necessitates the development of new antimicrobials and faster diagnostic tools. Conventional antimicrobial susceptibility testing is slow, relying on culture-based methods that delay effective treatment ...
Emily Salisbury   +13 more
doaj   +2 more sources

Unlocking potentials: the impact of meropenem, meropenem-vaborbactam, and ceftazidime-avibactam in combating carbapenem-resistant Enterobacter cloacae [PDF]

open access: yesAntimicrobial Agents and Chemotherapy
Carbapenem-resistant Enterobacterales (CREs) are recognized as an urgent public threat by the Centers for Disease Control and Prevention. This study assesses the activity of humanized serum concentrations for meropenem (2 g Q8h), meropenem-vaborbactam (4
Thomas Lavoie   +5 more
doaj   +2 more sources

Meropenem/Vaborbactam—A Mechanistic Review for Insight into Future Development of Combinational Therapies

open access: yesAntibiotics
Beta-lactam antibiotics have been a major climacteric in medicine for being the first bactericidal compound available for clinical use. They have continually been prescribed since their development in the 1940s, and their application has saved an ...
Trae Hillyer, Woo Shik Shin
doaj   +3 more sources

National Cohort of Compassionate Use of Meropenem–Vaborbactam: No Benefit over Meropenem for Pseudomonas aeruginosa

open access: yesAntibiotics
Background: Meropenem–vaborbactam (MEM-VAB) is a novel carbapenem-beta-lactamase-inhibitor combination that demonstrates activity against carbapenem-resistant (CR) Gram-negative bacteria, and more specifically KPC-producers, since vaborbactam is an ...
Aurélien Dinh   +24 more
doaj   +2 more sources

Susceptibility to novel antimicrobial agents and molecular epidemiology of carbapenem-resistant enterobacterales: a 9-year study in Central China [PDF]

open access: yesBMC Microbiology
Purpose This nine-year (2016–2024) surveillance study aimed to investigate the molecular epidemiology and antimicrobial susceptibility profiles of carbapenem-resistant Enterobacterales (CRE) in a tertiary hospital in Central China, with a focus on ...
Yungang Han   +12 more
doaj   +2 more sources

Comparative outcomes of ceftazidime-avibactam versus meropenem-vaborbactam for KPC-producing Enterobacterales infections [PDF]

open access: yesAntimicrobial Agents and Chemotherapy
Thirty-day mortality was similar in a propensity-score-weighted cohort of 73 patients with KPC-producing Enterobacterales infections treated with ceftazidime-avibactam or meropenem-vaborbactam.
Sara M. Karaba   +9 more
doaj   +2 more sources

Biochemical Activity of Vaborbactam [PDF]

open access: yesAntimicrobial Agents and Chemotherapy, 2020
The most common mechanism of resistance to β-lactams antibiotics in Gram-negative bacteria is production of β-lactamase enzymes capable of cleaving the β-lactam ring. Inhibition of β-lactamase activity with small-molecule drugs is a proven strategy to restore the potency of many β-lactam antibiotics.
Tsivkovski, Ruslan, Lomovskaya, Olga
openaire   +2 more sources

Home - About - Disclaimer - Privacy